Half-Year 2022 Financial and Clinical Trials Update

Esbriet Global sales CHFbn CER growth -14% Regional sales CER growth US -17% 0.6 0.5 Europe -2% 0.4 0.3 0.2 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 457m • US: Generics have entered the market in Q2 • EU: Generic entry expected soon CER-Constant Exchange Rates International -36% Roche 185

View entire presentation